首页> 外文OA文献 >Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial

【2h】

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial

机译：用索拉非尼或安慰剂治疗的放射性碘 - 难治性，高级分化的甲状腺癌患者的身体组成：III期决定试验的回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Olivier Huillard; Anne Jouinot; Camille Tlemsani; Marcia S. Brose; Jennifer Arrondeau; Gerold Meinhardt; Marc Fellous; Yoriko De Sanctis; Martin Schlumberger; Francois Goldwasser;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial [J] . Olivier Huillard, Anne Jouinot, Camille Tlemsani, Thyroid: official journal of the American Thyroid Association . 2019,第12期

机译：用Sorafenib或安慰剂治疗的放射性碘 - 难治性患者的身体组成，先进的分化甲状腺癌：第三阶段决策试验的回顾性分析
2. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer [J] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, BMC Cancer . 2011,第1期

机译：决策的原理和设计：一项双盲，随机，安慰剂对照的III期临床试验，评估索拉非尼在局部晚期或转移性放射性碘（RAI）难治性分化型甲状腺癌患者中的疗效和安全性
3. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial [J] . Brose Marcia S., Schlumbeger Martin, Jeffers Michael, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第24期

机译：分化甲状腺癌患者临床结果的生物标志物及其关联分析：Sorafenib阶段决定试验的细胞分析
4. Evaluation of Bone Marrow Irradiation by Area Under the Curve of Blood Counts Measurements in Hemodialyzed Patients with Differentiated Thyroid Cancer Treated with ~(131)Iodine. [C] . Mollerach AM, Rosa Diez G, Diehl M, Congress of the International Radiation Protection Association;IRPA 12 . 2010

机译：〜（131）碘治疗血液透析的分化型甲状腺癌患者的血细胞计数曲线下按面积评估骨髓照射。
5. Risk Factors of Salivary Gland Dysfunction in Radioiodine Treated Thyroid Cancer Patients and Automation of SPECT/CT Imaging Analysis of Mouse Thyroid [D] . Hollingsworth, Brynn Anne. 2017

机译：放射性碘治疗甲状腺癌患者唾液腺功能障碍的危险因素及小鼠甲状腺的SPECT / CT成像自动化
6. Rationale and design of decision: a double-blind randomized placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer [O] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, 2011

机译：决策的依据和设计：一项双盲随机安慰剂对照的III期临床试验评估索拉非尼在局部晚期或转移性放射性碘（RAI）-难治性分化型甲状腺癌患者中的疗效和安全性
7. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer [O] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, 2011

机译：决策的原理和设计：一项双盲，随机，安慰剂对照的III期临床试验，评估索拉非尼在局部晚期或转移性放射性碘（RAI）难治性分化型甲状腺癌患者中的疗效和安全性

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial

著录项

引文网络

相似文献

相关主题

期刊订阅